Serum miR-27a is a biomarker for the prognosis of non-small cell lung cancer patients receiving chemotherapy.

ABSTRACT:

Background

Lung cancer has a high incidence and a 5-year survival rate of less than 15%. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases. Chemotherapy and immunotherapy are the most frequently used alternative treatments for patients with advanced-stage NSCLC in whom surgery failed. Previous studies have suggested that miR-27a is involved in cancer development and progression. The purpose of this study was to investigate the clinical value of miR-27a in the prognosis of NSCLC patients after chemotherapy.

Methods

Flow cytometry was used to detect the apoptosis rate of SPC-A1 cells treated with optical cisplatin at different times. Simultaneously, the expression of miR-27a in supernatants and cells was detected. Fifty-two newly diagnosed

SUBMITTER: Xie E 

PROVIDER: S-EPMC8799153 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature